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Background: With aging of society the absolute number and the proportion of patients with cognitive deficits
increase. Multiple disorders and diseases can foster cognitive impairment, e.g., Alzheimer’s disease (AD), depressive
disorder, or polypharmacy.
Case presentation: A 74 year old man presented to the Old Age Psychiatry Service with cognitive deficits while
being treated for recurrent depressive episodes and essential tremor with Venlafaxine, Lithium, and Primidone.
Neuropsychological testing revealed a medio-temporal pattern of deficits with pronounced impairment of episodic
memory, particularly delayed recall. Likewise, cognitive flexibility, semantic fluency, and attention were impaired.
Positron emission tomography (PET) with fluorodeoxyglucose was performed and revealed a pattern of glucose
utilization deficit resembling AD. On cessation of treatment with Lithium and Primidone, cognitive performance
improved, particularly episodic memory performance and cognitive flexibility. Likewise, glucose metabolism
normalized. Despite normalization of both, clinical symptoms and glucose utilization, the patient remained worried
about possible underlying Alzheimer’s disease pathology. To rule this out, an amyloid-PET was performed. No
cortical amyloid was observed.
Conclusion: Pharmacological treatment of older subjects may mimic glucose metabolism and clinical symptoms of
Alzheimer’s disease. In the present case both, imaging and clinical findings, reversed to normal on change of
treatment. Amyloid PET is a helpful tool to additionally rule out underlying Alzheimer’s disease in situations of
clinical doubt even if clinical or other imaging findings are suggestive of Alzheimer’s disease.
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Alzheimer’s disease (AD) is a common cause for cogni-
tive impairment in old age [1]. Cognitive impairment
may also result from prescription of inappropriate drugs
in the elderly [2–4]. Long-term prescription of anti-
cholinergic drugs increases the risk for developing de-
mentia and AD [5, 6]. Thus, in elderly patients both
needs to be considered as a differential diagnosis of AD,
cognitive impairment as an acute or subacute side effect
of inappropriate medications, and dementia or AD on
long-term treatment with inappropriate medications.
At onset of AD, medio-temporal functions are reduced
[7, 8]. With spread of disease other functions are also af-
fected and a stage-dependent pattern of deficits unfolds [9].* Correspondence: matthias.riepe@uni-ulm.de
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layed recall, is compromised first, followed by impairment
of executive functions and visuo-construction [9–11]. Once
a cognitive deficit commences, the natural course of the
disease goes along with an increase of severity over time
without major fluctuation of severity and without reversal
of symptoms [9–11].
Several neurochemical and imaging biomarkers are
established to capture either amyloid metabolism or neu-
rodegeneration in AD [12]. Structural imaging targets
visualization of neurodegeneration. While no structural
imaging feature has perfect sensitivity or specificity, diag-
nostic algorithms using structural imaging have been pro-
posed to support the diagnosis of AD and differential
diagnosis of other dementias [13]. Likewise, imaging of
glucose metabolism or amyloid deposition can contribute
to the diagnosis and differential diagnosis of dementia dis-
orders [14]. Imaging with amyloid tracers has provided aicle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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Table 1 Neuropsychological findings at baseline and after
cessation of treatment with Lithium and Primidone
Baseline Follow-up
MMSE 28 30
Digit span forward 8 9
Digit span backward 5 6
Block span forward 6 7
Block span backward 5 7
Trail-Making Test A 121 78
Trail-Making Test B 278 103
CVLT I 3 4
CVLT V 4 9
Delayed recall 3 8
Semantic fluency (animals) 13 21
Phonematic fluency (P) 6 13
Phonematic fluency (S) 11 20
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been found well enough established to be used in criteria
recommended for diagnosing AD [15, 16]. At present,
however, it remains under discussion whether different
amyloid ligands perform equivalently [17, 18].
Decreased temporo-parietal glucose utilization as mea-
sured with positron emission tomography with fluorodeox-
yglucose (FDG-PET) is considered specific for Alzheimer’s
Disease [19, 20]. The degree of glucose hypometabolism
correlates with performance in appropriate neuropsycho-
logical tests [21].
Lithium is a widely used drug recommended for treat-
ment of bipolar disorder even in the elderly [22]. Its
clinical side effects, however, remain ambiguous. While
some reports demonstrate an impaired memory on
treatment with Lithium [23–25], another report in a
small number of patients finds memory unaffected on
treatment with Lithium [26]. Likewise, the findings on
the effect of Lithium on cerebral glucose metabolism are
ambiguous. An increased glucose metabolism was re-
ported in rodents [27] while another study reported glu-
cose utilization to be unchanged on low dosages of
Lithium and inhibited on higher dosages of Lithium
[28]. In humans, the evidence on glucose utilization is
sparse - a decrease in the hippocampus and the cerebel-
lum was reported [29] but it remained unclear, whether
reduction in glucose metabolism was related to clinical
symptoms [29]. In contrast, an increase of glucose
utilization on treatment with Lithium was found in the
posterior cingulate and in the orbitofrontal and dorsolat-
eral frontal cortex in pathological gamblers [30]. On in-
toxication with Lithium, a reduction of cerebral glucose
metabolism resembling Alzheimer’s disease has been
found [31].
Primidone is a standard medication for treatment of
essential tremor [32]. While cognitive side effects of
treatment with Primidone are frequent in the elderly
[33], the exact pattern of cognitive impairment on treat-
ment with Primidone has not been characterized. In
humans, an increase of glucose utilization was found on
cessation of treatment with Primidone [34]. However,
the increase of glucose utilization did not show a specific
pattern but rather was observed in all but one area of
the brain.
Here we report a patient that showed both, a pattern
of cognitive deficits and a pattern of glucose utilization
resembling Alzheimer’s disease while being treated for
recurrent depressive episodes and essential tremor with
Venlafaxine, Primidone, and Lithium.
Case presentation
A 74 year old man presented to the Old Age Psychiatry
Service with cognitive deficits, in particular deficits of
short term memory, while being treated for recurrentdepressive episode. Depressive disorder was diagnosed
1986 and under continuing treatment with Moclobemid
the depression was remitted until 2009. Several month
after cessation of treatment with Moclobemid depression
recurred and he was treated with Valproic acid and Ser-
traline. Due to incomplete remission, several antidepres-
sants were used until 2014. On admission the patient
was treated with Lithium (serum level 0.8 mmol/l (norm:
0.6 – 1.0 mmol/l)) and Venlafaxine. In addition, the
patient had familial essential tremor treated with
Primidone.
Neuropsychological testing on admission (Table 1) re-
vealed normal performance on cognitive (Mini-Mental
Status Examination 28/30) and affective scales (Geriatric
Depression Scale 3/15). Digit and block span forward
and backward were 8 and 5, and 6 and 5, respectively.
The German version of the California Verbal Learning
Test showed impaired word learning (3/16) in trial 1
with impaired delayed recall (4/16). Trail-Making Test A
and B were 121 and 278 s, respectively. Semantic fluency
was reduced to 13 animals per minute.
After cessation of treatment with Lithium and Primi-
done, the impairment on neuropsychological testing re-
versed (Table 1). Digit and block span forward and
backward improved to 9 and 6, and 7 and 7, respectively.
Verbal learning improved to 4 of 16 in trial I and 9 of 16
in delayed recall. Trail-Making Test A and B were 78 s
and 103 s, respectively. Semantic fluency improved to 23
animals per minute.
FDG-PET on admission showed reduced glucose me-
tabolism in temporo-parietal areas and the posterior cin-
gulum with a pattern characteristic for Alzheimer’s
disease. After cessation of treatment with Lithium and
Fig. 1 FDG-PET on a May,23rd, with an Alzheimer like glucose utilization deficit in temporo-parietal regions and the posterior cingulum and
b June, 25th, with a normalization of glucose utilization in all brain regions
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in all areas (Fig. 1).
To further rule out Alzheimer pathology an amyloid-
PET with was performed. No cortical amyloid deposition
was observed and thus, AD was ruled out (Fig. 2).
Discussion
Due to demographic changes an ever rising number of
elderly patients present to Medical Services with cognitive
impairment. Both, neurodegenerative diseases, amongst
which AD is the most common aetiology of dementia in
old age, and inappropriate medications [4] are frequent
causes of cognitive impairment in old age. Several lists
have been proposed to check for inappropriate medica-
tions in the elderly ever since the Beers criteria [35] have
been brought forward [36–39].
The diagnostic algorithm in the case presented here
cannot be generalized. Considering the known impact of
potentially inadequate drugs on cognition, it is in general
a straightforward procedure to cessate treatment with
these drugs or reduce their dosage. Due to changes in
pharmacokinetics and pharmacodynamics it may be
worthwhile in general to consider decrease of dosage in
the elderly even when serum concentration of suspicious
drugs are within the therapeutic range [40, 41], but no
clear-cut recommendations are established. In the presentFig. 2 Amyloid-PET on June, 25th, demonstrating the absence of cortical acase, however, the patient had had multiple complications
on change of prior medications: on change of antidepres-
sive treatment several years ago the clinical situation of
the patient had worsened and at first the patient was re-
luctant to change antidepressive medication again. Like-
wise, essential tremor was burdensome for the patient and
while treatment with propranolol was tried some years
ago it had to be abolished for reasons of cardiac side ef-
fects so that the patient was reluctant to change treatment
with Primidone.
Both, neuropsychological assessment and positron emis-
sion tomography imaging, have characteristic patterns in
the early stages of Alzheimer’s disease. Cognition at onset
of disease is characterized by a medio-temporal deficit [9]
with predominant deficits of episodic memory (see above).
At this stage, FDG-PET is characterized by a temporo-
parietal glucose hypometabolism [19, 20]. Both findings
were present in the patient described above and both find-
ings reverted to normal when treatment with Primidone
and Lithium was stopped.
It has been reported that Primidone reduces cerebral
glucose metabolism [34]. However, reduction of glucose
metabolization under treatment with primidone affects
almost all brain regions and cannot explain a specific
pattern of glucose utilization deficit such as the one
observed in the patient reported here. In contrast, amyloid in all brain regions
Riepe et al. BMC Psychiatry  (2015) 15:157 Page 5 of 6pattern of glucose utilization deficit resembling Alzhei-
mer’s disease has been reported on intoxication with
Lithium [31]. However, Lithium levels in the patient re-
ported here were within the therapeutic range as were
serum levels of Primidone. Thus, this case is the first to
demonstrate that an Alzheimer-like pattern of glucose
utilization deficit can occur while psychotropic and
neurotropic substances are within normal range.
The course of clinical symptoms and glucose utilization
findings on cessation of treatment with Lithium and Primi-
done argued that the Alzheimer-concordant neuropsycho-
logical and imaging findings were a false positive finding
due to the pharmacological treatment. We substantiated
this interpretation with amyloid PET where no cortical
amyloid whatsoever was observed.
Half a year after the diagnostic procedures and change
of therapy the patient reported to be in good mood and to
have no impairment in everyday functions, in particular
no impairment with eating and writing, due to residual
symptoms of essential tremor.
Conclusion
Pharmacological treatment of older subjects may mimic
glucose metabolism and clinical symptoms resembling
Alzheimer’s disease – this further substantiates the general
recommendation to reduce or cessate treatment with po-
tentially harmful drugs known to impair cognition in the
elderly. Both, imaging and clinical findings reversed on
cessation of treatment. Amyloid PET is a helpful tool to
additionally rule out underlying Alzheimer’s disease in sit-
uations of clinical doubt even if clinical or other imaging
findings are suggestive of Alzheimer’s disease.
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